Phase I I/UCRC Clemson University Site: Advanced Mammalian Biomanufacturing Innovation Center (AMBIC)
I 期 I/UCRC 克莱姆森大学基地:先进哺乳动物生物制造创新中心 (AMBIC)
基本信息
- 批准号:1624641
- 负责人:
- 金额:$ 75万
- 依托单位:
- 依托单位国家:美国
- 项目类别:Continuing Grant
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-09-01 至 2022-08-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Phase I I/UCRC Clemson University Site: Advanced Mammalian Biomanufacturing Innovation Center (AMBIC).Johns Hopkins University, University of Delaware, Clemson University, and University of Massachusetts-Lowell have jointly established a multi-university, Phase I I/UCRC entitled the Advanced Mammalian Biomanufacturing Innovation Center (AMBIC). Over the past two decades, the biopharmaceutical industry has emerged as one of the major manufacturing industries and engines of growth in the US economy. Biomanufacturing represents nearly 2% of the total US GDP and its fraction is expanding. Much of biomanufacturing involves the use of cells to make medicines. Examples of these types of medicines include cancer medicines and vaccines. A key element in developing these medicines is the need to establish complex manufacturing processes. AMBIC will implement engineering innovations to enhance the capabilities of our nation to manufacture these important life-extending and life-saving medicines. Such improvements will improve the competitiveness of US biomanufacturing in coming decades leading to more economic investment by these companies and more jobs for American workers. The mission of AMBIC is to develop enabling technologies, knowledge, design tools and methods that apply and integrate high-throughput and genome-based technologies to fast-track advanced biomanufacturing processes. AMBIC is the first I/UCRC dedicated to mammalian cell culture upstream development focusing on Chinese hamster ovary (CHO) cells, the principal biopharmaceutical production host of industry. AMBIC will bring together leading academic and industrial biotechnologists focused on mammalian cell culture manufacturing at a pre-competitive research level to address the complex problems in biopharmaceutical manufacturing. This multi-university center will allow AMBIC to leverage the skills and the expertise of many faculty members across the Sites. AMBIC will be a critical catalyst towards maintaining national excellence in biopharmaceutical production by conducting research in: 1) Understanding Industrially-Relevant Biology (e.g., all -omics, bioinformatics, process and product quality, etc.); 2) Process Monitoring & Control (e.g., analytics, instrumentation, data mining and modeling); 3) Consensus and Standardization Issues (e.g., standards, simple fingerprints, raw material issues, regulatory issues, forensic bioprocessing, clonality). Through systems-level biology analysis, novel cell line development, bioreactor optimization, and advanced analytics, AMBIC will provide transformative solutions that can lower biomanufacturing costs and improve bioprocessing efficiency. Most importantly, these advances may ultimately serve to make more biopharmaceuticals available to patients that need them and lower overall health care costs for consumers. In addition, AMBIC will establish and maintain a pipeline of educated and motivated students at multiple levels for careers in biopharmaceutical manufacturing and development. Collaborations with corporate partners will enable the students to work on the most pressing problems that the industry faces. Furthermore, this center will serve to engage and excite students from under-represented minority populations to pursue a career in life sciences, engineering, or related STEM fields. An important part of the AMBIC activities and a committed goal of the PI's is to increase the participation of women and under-represented minorities in STEM disciplines by energizing students from all backgrounds about the exciting opportunities to help others through STEM careers in biotechnology and biomedicine.
I 期 I/UCRC 克莱姆森大学基地:先进哺乳动物生物制造创新中心 (AMBIC)。约翰·霍普金斯大学、特拉华大学、克莱姆森大学和马萨诸塞大学洛厄尔分校联合建立了多所大学,I 期 I/UCRC 名为先进哺乳动物生物制造创新中心生物制造创新中心(AMBIC)。 过去二十年来,生物制药行业已成为美国主要制造业和经济增长引擎之一。 生物制造占美国 GDP 总量的近 2%,而且这一比例正在扩大。许多生物制造涉及使用细胞来制造药物。 这些类型的药物的例子包括癌症药物和疫苗。开发这些药物的一个关键要素是需要建立复杂的制造工艺。 AMBIC 将实施工程创新,以增强我国生产这些重要的延长生命和挽救生命的药物的能力。 这些改进将提高美国生物制造在未来几十年的竞争力,从而为这些公司带来更多的经济投资,并为美国工人提供更多的就业机会。 AMBIC 的使命是开发应用和集成高通量和基于基因组的技术的支持技术、知识、设计工具和方法,以快速跟踪先进的生物制造工艺。 AMBIC 是第一个致力于哺乳动物细胞培养上游开发的 I/UCRC,专注于中国仓鼠卵巢 (CHO) 细胞,这是行业主要的生物制药生产宿主。 AMBIC 将汇集领先的学术和工业生物技术专家,专注于竞争前研究水平的哺乳动物细胞培养制造,以解决生物制药制造中的复杂问题。 这个多大学中心将使 AMBIC 能够利用各个站点许多教员的技能和专业知识。 AMBIC 将通过开展以下研究来成为保持国家生物制药生产卓越性的关键催化剂: 1) 了解工业相关生物学(例如,全组学、生物信息学、工艺和产品质量等); 2) 过程监控(例如分析、仪器仪表、数据挖掘和建模); 3) 共识和标准化问题(例如标准、简单指纹、原材料问题、监管问题、法医生物处理、克隆性)。 通过系统级生物学分析、新型细胞系开发、生物反应器优化和高级分析,AMBIC 将提供能够降低生物制造成本并提高生物加工效率的变革性解决方案。 最重要的是,这些进步最终可能有助于为有需要的患者提供更多的生物药品,并降低消费者的总体医疗保健成本。 此外,AMBIC 将建立并维持一个受过教育、积极进取的多层次学生管道,以从事生物制药制造和开发职业。 与企业合作伙伴的合作将使学生能够解决行业面临的最紧迫的问题。 此外,该中心还将吸引和激励少数族裔学生在生命科学、工程或相关 STEM 领域从事职业。 AMBIC 活动的一个重要组成部分和 PI 的坚定目标是通过激励来自不同背景的学生了解通过生物技术和生物医学领域的 STEM 职业帮助他人的令人兴奋的机会,从而增加女性和代表性不足的少数群体对 STEM 学科的参与。
项目成果
期刊论文数量(6)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
PID controls: The forgotten bioprocess parameters
- DOI:10.1007/s43938-022-00008-z
- 发表时间:2022-01-01
- 期刊:
- 影响因子:0
- 作者:Harcum, S.W.;Elliott, K.S.;Lee, K.H.
- 通讯作者:Lee, K.H.
Rapid metal speciation of cell culture media using reversed‐phase separations and inductively coupled plasma optical emission spectrometry
- DOI:10.1002/btpr.3311
- 发表时间:2022-10
- 期刊:
- 影响因子:2.9
- 作者:Sarah K. Wysor;Katja A. Hall;R. K. Marcus
- 通讯作者:Sarah K. Wysor;Katja A. Hall;R. K. Marcus
Induced pluripotent stem cells can utilize lactate as a metabolic substrate to support proliferation
- DOI:10.1002/btpr.3090
- 发表时间:2020-11-04
- 期刊:
- 影响因子:2.9
- 作者:Odenwelder, Daniel C.;Lu, Xiaoming;Harcum, Sarah W.
- 通讯作者:Harcum, Sarah W.
Generation of reference cell lines, media, and a process platform for CHO cell biomanufacturing
生成用于 CHO 细胞生物制造的参考细胞系、培养基和工艺平台
- DOI:10.1002/bit.28290
- 发表时间:2022
- 期刊:
- 影响因子:3.8
- 作者:Cordova, Lauren T.;Dahodwala, Hussain;Elliott, Kathryn S.;Baik, Jongyoun;Odenewelder, Daniel C.;Nmagu, Douglas;Skelton, Bradley A.;Uy, Lisa;Klaubert, Stephanie R.;Synoground, Benjamin F.
- 通讯作者:Synoground, Benjamin F.
Sensitive real-time on-line estimator for oxygen transfer rates in fermenters
发酵罐中氧气传输率的灵敏实时在线估算器
- DOI:10.1016/j.jbiotec.2022.09.005
- 发表时间:2022
- 期刊:
- 影响因子:4.1
- 作者:Trout, Marshall;Harcum, Sarah W.;Groff, Richard E.
- 通讯作者:Groff, Richard E.
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Sarah Harcum其他文献
Sarah Harcum的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Sarah Harcum', 18)}}的其他基金
IUCRC Phase II+ Clemson University: Advanced Mammalian Biomanufacturing Innovation Center (AMBIC)
IUCRC 二期克莱姆森大学:先进哺乳动物生物制造创新中心 (AMBIC)
- 批准号:
2100442 - 财政年份:2021
- 资助金额:
$ 75万 - 项目类别:
Continuing Grant
RII Track-2 FEC: Advanced Biomanufacturing: Catalyzing Improved Host Development and High Quality Medicines through Genome to Phenome Predictions
RII Track-2 FEC:先进生物制造:通过基因组到表型组预测促进宿主发育和高质量药物的改进
- 批准号:
1736123 - 财政年份:2017
- 资助金额:
$ 75万 - 项目类别:
Cooperative Agreement
Collaborative Research: Planning Grant: I/UCRC for Advanced Mammalian Biomanufacturing Innovation Center (AMBIC)
合作研究:规划补助金:I/UCRC 先进哺乳动物生物制造创新中心 (AMBIC)
- 批准号:
1464459 - 财政年份:2015
- 资助金额:
$ 75万 - 项目类别:
Standard Grant
EAGER: Transcriptome analysis of CHO cells to improve productivity and control protein aggregation
EAGER:CHO 细胞的转录组分析,以提高生产力并控制蛋白质聚集
- 批准号:
1218345 - 财政年份:2012
- 资助金额:
$ 75万 - 项目类别:
Standard Grant
SGER: Inclusion body formation in E. coli: What triggers this outcome?
SGER:大肠杆菌中包涵体的形成:是什么触发了这一结果?
- 批准号:
0738162 - 财政年份:2007
- 资助金额:
$ 75万 - 项目类别:
Standard Grant
CAREER: Stress Response in Recombinant Eschericia coli: A Research and Educational Tool
职业:重组大肠杆菌的应激反应:研究和教育工具
- 批准号:
0303782 - 财政年份:2002
- 资助金额:
$ 75万 - 项目类别:
Continuing Grant
CAREER: Stress Response in Recombinant Eschericia coli: A Research and Educational Tool
职业:重组大肠杆菌的应激反应:研究和教育工具
- 批准号:
9732957 - 财政年份:1998
- 资助金额:
$ 75万 - 项目类别:
Continuing Grant
Glycosylation of Recombinant Proteins Research Planning Grant
重组蛋白糖基化研究计划资助
- 批准号:
9711130 - 财政年份:1997
- 资助金额:
$ 75万 - 项目类别:
Standard Grant
相似海外基金
I/UCRC Phase III Iowa State University: Center for Advanced Non-Ferrous Structural Alloys (CANFSA)
I/UCRC 第三期爱荷华州立大学:先进有色金属结构合金中心 (CANFSA)
- 批准号:
2137250 - 财政年份:2022
- 资助金额:
$ 75万 - 项目类别:
Standard Grant
I/UCRC Phase II: The Pennsylvania State University: Center for Atomically Thin Multifunctional Coatings (ATOMIC)
I/UCRC 第二阶段:宾夕法尼亚州立大学:原子薄多功能涂层中心 (ATOMIC)
- 批准号:
2113864 - 财政年份:2021
- 资助金额:
$ 75万 - 项目类别:
Continuing Grant
Phase II I/UCRC WPI: Center for Robots and Sensors for the Human Well-Being
II 期 I/UCRC WPI:人类福祉机器人和传感器中心
- 批准号:
1939061 - 财政年份:2020
- 资助金额:
$ 75万 - 项目类别:
Continuing Grant
Phase I I/UCRC at Florida International University: Center for Wind Hazard and Infrastructure Performance (WHIP)
佛罗里达国际大学 I/UCRC 第一阶段:风灾和基础设施性能中心 (WHIP)
- 批准号:
1841503 - 财政年份:2019
- 资助金额:
$ 75万 - 项目类别:
Continuing Grant
I/UCRC Phase II: Collaborative Research: Center for Pharmaceutical Development (CPD)
I/UCRC 第二阶段:合作研究:药物开发中心 (CPD)
- 批准号:
1939164 - 财政年份:2019
- 资助金额:
$ 75万 - 项目类别:
Continuing Grant